Catal­ent wins bid­ding war to take on UK's VMIC

When a source from the UK gov­ern­ment talked to the Fi­nan­cial Times back in De­cem­ber about the po­ten­tial sale of a ready-made vac­cine man­u­fac­tur­ing site, one thing was made clear: Stake­hold­ers want­ed to sell it to “some­one who knows how to run it.” Four months lat­er, it looks like Catal­ent is that some­one.

A bi­o­log­ics man­u­fac­tur­ing and de­vel­op­ment cen­ter al­ready in the midst of con­struc­tion in the UK now be­longs to Catal­ent, and will get an ad­di­tion­al $160 mil­lion in­vest­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER